Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
AmerisourceBergen is one of the three dominant pharmaceutical wholesale distributors in the United States, operating a high-volume, low-margin logistics network that delivers prescription drugs from manufacturers to retail pharmacies, hospitals, and specialty providers. The company controls approximately 30-35% of the U.S. pharmaceutical distribution market alongside McKesson and Cardinal Health, with competitive advantages stemming from scale economies, manufacturer relationships, and integrated specialty distribution capabilities including oncology and rare disease therapies. Stock performance is driven by prescription volume growth, specialty pharma mix shift, generic drug pricing dynamics, and the company's ability to maintain operating leverage despite razor-thin margins.
AmerisourceBergen operates as a high-velocity intermediary between pharmaceutical manufacturers and dispensing providers, earning narrow distribution fees (typically 2-4% of wholesale acquisition cost) on massive transaction volumes exceeding $320 billion annually. Profitability depends on operational efficiency, inventory management, and negotiated service fees with manufacturers rather than traditional buy-sell spreads. The company generates returns through scale advantages in logistics infrastructure, automated distribution centers processing 30+ million prescription units daily, and favorable payment terms creating positive working capital dynamics. Specialty distribution commands higher margins (8-12% gross margins vs 3-4% for traditional wholesale) due to value-added services including patient financial assistance, adherence monitoring, and cold-chain logistics for biologics. Generic drug sourcing programs and manufacturer rebates provide additional margin enhancement, though generic deflation cycles can pressure profitability.
Prescription volume trends and utilization rates across retail and specialty channels, particularly GLP-1 diabetes/obesity drugs and oncology therapies driving high-value specialty mix
Generic drug pricing environment and timing of major brand-to-generic conversions affecting gross margin profiles
Contract renewals and pricing negotiations with major retail pharmacy customers (Walgreens, CVS, independent pharmacies) and group purchasing organizations
Specialty pharmaceutical revenue growth rates, particularly in oncology and rare disease categories commanding 2-3x higher margins than traditional distribution
Regulatory and litigation developments related to opioid settlements, with $6+ billion in aggregate settlement obligations affecting cash flow through 2038
Vertical integration by retail pharmacy chains and health systems building direct manufacturer relationships or acquiring their own distribution capabilities, potentially disintermediating wholesalers
Government drug pricing reform including Medicare negotiation provisions in Inflation Reduction Act, potential Medicaid rebate changes, and importation proposals that could compress manufacturer pricing and reduce distribution economics
Ongoing opioid litigation with $6.6 billion settlement obligations extending through 2038, creating annual cash outflows of $300-400 million and residual litigation risk from non-settling states and municipalities
Intense competition from McKesson and Cardinal Health in a consolidated oligopoly where customer contract losses can materially impact volumes (e.g., loss of major retail chain contract)
Pricing pressure from large pharmacy chains and PBMs leveraging scale to negotiate lower distribution fees, with limited ability to offset through efficiency gains given already-optimized operations
Amazon's potential entry into pharmaceutical distribution through PillPack acquisition and Amazon Pharmacy expansion, though specialty distribution complexity provides near-term moat
Elevated leverage with Debt/Equity of 4.15x and net debt approaching $9 billion, limiting financial flexibility and creating refinancing risk if credit markets tighten
Current ratio of 0.92 indicates working capital deficit, though this is typical for the business model and managed through revolving credit facilities; disruption to credit access could strain liquidity
Pension and post-retirement benefit obligations, though less material than industrial companies, still represent $200-300 million in underfunded liabilities sensitive to discount rate assumptions
low - Pharmaceutical distribution is highly recession-resistant as prescription drug utilization is non-discretionary and driven by chronic disease prevalence and aging demographics rather than economic cycles. However, severe recessions can modestly impact elective procedures and new prescription starts, while unemployment affecting insurance coverage can shift payer mix toward lower-margin Medicaid business. The company benefits from demographic tailwinds as aging population drives 3-5% annual prescription volume growth independent of GDP.
Rising interest rates create modest headwinds through higher borrowing costs on the company's $10+ billion debt load (Debt/Equity of 4.15x), increasing annual interest expense by $30-50 million per 100 basis point rate increase. However, the business model generates positive working capital (vendors paid in 30-45 days while customers pay in 20-25 days), allowing the company to benefit from higher short-term investment yields on cash balances. Valuation multiples compress modestly in rising rate environments as investors rotate from defensive healthcare stocks to cyclicals, though the 8.9% FCF yield provides downside support.
Moderate credit exposure through accounts receivable from retail pharmacy customers, with concentration risk as top 10 customers represent 60-70% of revenue. Independent pharmacy bankruptcies during economic stress can create bad debt expense, though relationships with large chains (Walgreens, CVS) provide stability. The company maintains credit insurance and factoring arrangements to mitigate exposure. Tightening credit conditions can pressure smaller pharmacy customers' ability to finance inventory purchases, potentially slowing volume growth.
value - The stock trades at 0.2x Price/Sales and generates 8.9% FCF yield, attracting value investors seeking defensive healthcare exposure with steady cash generation. The combination of low valuation multiples, modest single-digit revenue growth, and capital return through dividends and buybacks appeals to income-oriented investors. However, elevated leverage (36.6x Price/Book driven by financial engineering) and litigation overhangs deter growth investors seeking clean balance sheets.
low - Healthcare distribution stocks exhibit below-market volatility (estimated beta 0.7-0.8) due to non-cyclical revenue streams and predictable cash flows. Daily price movements are typically muted except during earnings releases, major contract announcements, or regulatory developments. The stock tends to outperform during market downturns as investors rotate to defensive sectors, while lagging in strong bull markets.
